Abstract
BackgroundAdoptive cell transfer (ACT) with autologous tumor-infiltrating lymphocytes (TILs) has proven to be one of the most successful immune therapies with overall response rates of around 50% in patients with...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
